Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations
- PMID: 15726496
- PMCID: PMC1199304
- DOI: 10.1086/429256
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations
Abstract
Autosomal dominant parkinsonism has been attributed to pathogenic amino acid substitutions in leucine-rich repeat kinase 2 (LRRK2). By sequencing multiplex families consistent with a PARK8 assignment, we identified a novel heterozygous LRRK2 mutation. A referral sample of 248 affected probands from families with autosomal dominant parkinsonism was subsequently assessed; 7 (2.8%) were found to carry a heterozygous LRRK2 6055G-->A transition (G2019S). These seven patients originate from the United States, Norway, Ireland, and Poland. In samples of patients with idiopathic Parkinson disease (PD) from the same populations, further screening identified six more patients with LRRK2 G2019S; no mutations were found in matched control individuals. Subsequently, 42 family members of the 13 probands were examined; 22 have an LRRK2 G2019S substitution, 7 with a diagnosis of PD. Of note, all patients share an ancestral haplotype indicative of a common founder, and, within families, LRRK2 G2019S segregates with disease (multipoint LOD score 2.41). Penetrance is age dependent, increasing from 17% at age 50 years to 85% at age 70 years. In summary, our study demonstrates that LRRK2 G2019S accounts for parkinsonism in several families within Europe and North America. Our work highlights the fact that a proportion of clinically typical, late-onset PD cases have a genetic basis.
Figures





Similar articles
-
A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.Eur J Neurol. 2007 Apr;14(4):413-7. doi: 10.1111/j.1468-1331.2007.01685.x. Eur J Neurol. 2007. PMID: 17388990
-
LRRK2 mutations are a common cause of Parkinson's disease in Spain.Eur J Neurol. 2006 Apr;13(4):391-4. doi: 10.1111/j.1468-1331.2006.01256.x. Eur J Neurol. 2006. PMID: 16643318
-
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families.Mov Disord. 2007 Jan;22(1):55-61. doi: 10.1002/mds.21180. Mov Disord. 2007. PMID: 17115391
-
Clinical features of LRRK2 parkinsonism.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S205-8. doi: 10.1016/S1353-8020(09)70815-6. Parkinsonism Relat Disord. 2009. PMID: 20082991 Review.
-
PARK8 LRRK2 parkinsonism.Curr Neurol Neurosci Rep. 2006 Jul;6(4):287-94. doi: 10.1007/s11910-006-0020-0. Curr Neurol Neurosci Rep. 2006. PMID: 16822348 Review.
Cited by
-
Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.Hum Mol Genet. 2021 Apr 30;30(6):454-466. doi: 10.1093/hmg/ddab058. Hum Mol Genet. 2021. PMID: 33640967 Free PMC article.
-
Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.Neurology. 2015 Jan 27;84(4):399-406. doi: 10.1212/WNL.0000000000001189. Epub 2014 Dec 24. Neurology. 2015. PMID: 25540317 Free PMC article.
-
LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors.Mol Neurodegener. 2012 May 30;7:25. doi: 10.1186/1750-1326-7-25. Mol Neurodegener. 2012. PMID: 22647713 Free PMC article.
-
Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.Neurology. 2012 Sep 4;79(10):1027-32. doi: 10.1212/WNL.0b013e3182684646. Epub 2012 Aug 22. Neurology. 2012. PMID: 22914834 Free PMC article.
-
Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson's Disease.Genes (Basel). 2022 Oct 25;13(11):1937. doi: 10.3390/genes13111937. Genes (Basel). 2022. PMID: 36360174 Free PMC article. Review.
References
Electronic-Database Information
-
- GenBank, http://www.ncbi.nih.gov/Genbank/ (for LRRK2 [accession number AY792511], rat [accession number XP_235581], mouse [accession number AAH34074], frog [accession number AAH76853], and puffer fish [accession number CAG05593])
-
- International HapMap Project, http://www.hapmap.org/
-
- MAP-O-MAT, http://compgen.rutgers.edu/mapomat/ (for version 1.1)
-
- Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for PARK1, PARK4, PARK2,PARK6, PARK7, and PARK8)
References
-
- Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW (2003) The role of pathogenic DJ-1 mutations in Parkinson’s disease. Ann Neurol 54:283–286 - PubMed
-
- Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256–259 - PubMed
-
- Bosgraaf L, Van Haastert PJ (2003) Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 1643:5–10 - PubMed
-
- Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A (2004) α-Synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364:1167–1169 - PubMed
-
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954 - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials